Gazzola Anna, Navari Mohsen, Mannu Claudia, Donelli Riccardo, Etebari Maryam, Piccaluga Pier Paolo
Hematopathology Unit, IRCCS Azienda Opedaliera-Universitaria di Bologna S. Orsola-Malpighi, 40138 Bologna, Italy.
Department of Medical Biotechnology, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh 95196-33787, Iran.
Cancers (Basel). 2023 Sep 19;15(18):4624. doi: 10.3390/cancers15184624.
Multiplex PCR based on consensus primers followed by capillary electrophoresis and Sanger sequencing are considered as the gold standard method for the evaluation of clonality and somatic hypermutation in lymphoid malignancies. As an alternative, the next-generation sequencing (NGS) of immune receptor genes has recently been proposed as a solution, due to being highly effective and sensitive. Here, we designed a phase III diagnostic accuracy study intended to compare the current gold standard methods versus the first commercially available NGS approaches for testing immunoglobulin heavy chain gene rearrangements.
We assessed IGH rearrangements in 68 samples by means of both the NGS approach (LymphoTrack IGH assay, and LymphoTrack IGH somatic hypermutation assay, run on Illumina MiSeq) and capillary electrophoresis/Sanger sequencing to assess clonality and somatic hypermutations (SHM).
In comparison to the routine capillary-based analysis, the NGS clonality assay had an overall diagnostic accuracy of 96% (63/66 cases). Other studied criteria included sensitivity (95%), specificity (100%), positive predictive value (100%) and negative predictive value (75%). In discrepant cases, the NGS results were confirmed by a different set of primers that provided coverage of the IGH leader sequence. Furthermore, there was excellent agreement of the SHM determination with both the LymphoTrack FR1 and leader assays when compared to the Sanger sequencing analysis (84%), with NGS able to assess the SHM rate even in cases where the conventional approach failed.
Overall, conventional Sanger sequencing and next-generation-sequencing-based clonality and somatic hypermutation analyses gave comparable results. For future use in a routine diagnostic workflow, NGS-based approaches should be evaluated prospectively and an analysis of cost-effectiveness should be performed.
基于共有引物的多重聚合酶链反应(PCR),随后进行毛细管电泳和桑格测序,被认为是评估淋巴系统恶性肿瘤克隆性和体细胞超突变的金标准方法。作为一种替代方法,免疫受体基因的下一代测序(NGS)最近被提出作为一种解决方案,因为它高效且灵敏。在此,我们设计了一项III期诊断准确性研究,旨在比较当前的金标准方法与第一种可用于检测免疫球蛋白重链基因重排的商业可用NGS方法。
我们通过NGS方法(LymphoTrack IGH检测和LymphoTrack IGH体细胞超突变检测,在Illumina MiSeq上运行)和毛细管电泳/桑格测序评估68个样本中的IGH重排,以评估克隆性和体细胞超突变(SHM)。
与常规的基于毛细管的分析相比,NGS克隆性检测的总体诊断准确性为96%(66例中的63例)。其他研究标准包括敏感性(95%)、特异性(100%)、阳性预测值(100%)和阴性预测值(75%)。在存在差异的病例中,NGS结果通过一组不同的引物得到证实,该引物覆盖了IGH前导序列。此外,与桑格测序分析相比,SHM测定与LymphoTrack FR1和前导序列检测的一致性都非常好(84%),NGS甚至能够在传统方法失败的情况下评估SHM率。
总体而言,传统的桑格测序以及基于下一代测序的克隆性和体细胞超突变分析给出了可比的结果。对于未来在常规诊断工作流程中的应用,基于NGS的方法应进行前瞻性评估,并应进行成本效益分析。